NEW YORK--(BUSINESS WIRE)--Dec 10, 2024--

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to the Company's initial public offering conducted on February 7, 2024 (the "IPO"). Kyverna is a "clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases."

kAmu@C >@C6 :?7@C>2E:@?[ DF3>:E 2 k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauC@D6?=682=]4@>TauDF3>:E\7@C>TauTbu42D60:5TbsbaabhU2>Aj6D966Eldc'ed_eaU2>Aj?6HD:E6>:5la_ac'a'_bdefa'U2>Aj=2?l6?\&$U2>Aj2?49@Cl7@C>U2>Aj:?56Il'U2>Aj>5dld_hhd2dg6fa223bdhag2dbace36'7573Q C6=lQ?@7@==@HQ D92A6lQC64EQm7@C>k^2m[ k2 9C67lQ>2:=E@i42D6oC@D6?=682=]4@>Q C6=lQ?@7@==@HQ D92A6lQC64EQm6>2:=k^2m 2EE@C?6J !9:==:A z:>[ @C 8:G6 FD 2 42== 2E gee\fef\bedb]k^Am kAm%96 p==682E:@?Di #@D6? {2H u:C> :D x?G6DE:82E:?8 E96 p==682E:@?D E92E zJG6C?2 %96C2A6FE:4D[ x?4] W}p$sp"i z*%)X |:D=65 x?G6DE@CD #682C5:?8 :ED qFD:?6DD ~A6C2E:@?D]k^AmkAmp44@C5:?8 E@ E96 =2HDF:E[ E96 C68:DEC2E:@? DE2E6>6?E 2?5 AC@DA64EFD FD65 E@ 67764EF2E6 zJG6C?2'D x!~ >:DDE2E65 2?5^@C @>:EE65 724ED 4@?46C?:?8 E96 C6DF=ED @7 zJG6C?2'D @?8@:?8 6G2=F2E:@? @7 z*'\'_'[ zJG6C?2'D =625 AC@5F4E 42?5:52E6[ :? 4=:?:42= EC:2=D] $A64:7:42==J[ zJG6C?2 E@FE65 A2E:6?E ":>AC@G6>6?E" :? 46CE2:? :?5:42E@CD H9:=6 72:=:?8 E@ 5:D4=@D6 25G6CD6 52E2 C682C5:?8 @?6 @7 zJG6C?2'D EC:2=D[ H9:49 25G6CD6 52E2 H2D <?@H? E@ zJG6C?2 2E E96 E:>6 @7 E96 x!~] (96? E96 ECF6 56E2:=D 6?E6C65 E96 >2C<6E[ E96 =2HDF:E 4=2:>D E92E :?G6DE@CD DF776C65 52>286D]k^AmkAm(92E }@Hi *@F >2J 36 6=:8:3=6 E@ A2CE:4:A2E6 :? E96 4=2DD 24E:@? 282:?DE zJG6C?2 %96C2A6FE:4D[ x?4] $92C69@=56CD H9@ H2?E E@ D6CG6 2D =625 A=2:?E:77 7@C E96 4=2DD >FDE 7:=6 E96:C >@E:@?D H:E9 E96 4@FCE 3J u63CF2CJ f[ a_ad] p =625 A=2:?E:77 :D 2 C6AC6D6?E2E:G6 A2CEJ H9@ 24ED @? 3692=7 @7 @E96C 4=2DD >6>36CD :? 5:C64E:?8 E96 =:E:82E:@?] *@F 5@ ?@E 92G6 E@ A2CE:4:A2E6 :? E96 42D6 E@ 36 6=:8:3=6 7@C 2 C64@G6CJ] x7 J@F 49@@D6 E@ E2<6 ?@ 24E:@?[ J@F 42? C6>2:? 2? 23D6?E 4=2DD >6>36C] u@C >@C6 :?7@C>2E:@?[ 4=:4< k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauC@D6?=682=]4@>Tau42D6Tau<JG6C?2\E96C2A6FE:4D\:?4TauU2>Aj6D966Eldc'ed_eaU2>Aj?6HD:E6>:5la_ac'a'_bdefa'U2>Aj=2?l6?\&$U2>Aj2?49@Cl96C6U2>Aj:?56IlaU2>Aj>5dl'fca633''46aeg4_bh47f6gbd42dc7hbQ C6=lQ?@7@==@HQ D92A6lQC64EQm96C6k^2m]k^AmkAmp== C6AC6D6?E2E:@? :D @? 2 4@?E:?86?4J 766 32D:D] $92C69@=56CD A2J ?@ 766D @C 6IA6?D6D]k^AmkAmp3@FE #@D6? {2H u:C>i $@>6 =2H 7:C>D :DDF:?8 C6=62D6D 23@FE E9:D >2EE6C 5@ ?@E 24EF2==J =:E:82E6 D64FC:E:6D 4=2DD 24E:@?D] #@D6? {2H u:C> 5@6D] k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEATbpTauTauHHH]C@D6?=682=]4@>TauU2>Aj6D966Eldc'ed_eaU2>Aj?6HD:E6>:5la_ac'a'_bdefa'U2>Aj=2?l6?\&$U2>Aj2?49@Cl#@D6?Z{2HZu:C>U2>Aj:?56IlbU2>Aj>5dle76c5fg4ab2f'6c'53a5446g7e6d3g5fQ C6=lQ?@7@==@HQ D92A6lQC64EQm#@D6? {2H u:C>k^2m :D 2 C64@8?:K65 =6256C :? D92C69@=56C C:89ED =:E:82E:@?[ 565:42E65 E@ 96=A:?8 D92C69@=56CD C64@G6C =@DD6D[ :>AC@G:?8 4@CA@C2E6 8@G6C?2?46 DECF4EFC6D[ 2?5 9@=5:?8 4@>A2?J 6I64FE:G6D 244@F?E23=6 7@C E96:C HC@?85@:?8] $:?46 :ED :?46AE:@?[ #@D6? {2H u:C> 92D @3E2:?65 @G6C S' 3:==:@? 7@C D92C69@=56CD]k^AmkAmu@==@H FD 7@C FA52E6D @? {:?<65x?i k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]=:?<65:?]4@>Tau4@>A2?JTauE96\C@D6?\=2H\7:C>U2>Aj6D966Eldc'ed_eaU2>Aj?6HD:E6>:5la_ac'a'_bdefa'U2>Aj=2?l6?\&$U2>Aj2?49@Cl9EEADTbpTauTauHHH]=:?<65:?]4@>Tau4@>A2?JTauE96\C@D6?\=2H\7:C>U2>Aj:?56IlcU2>Aj>5dlf_a52346__f_f2c63'5b56gd3cedfag7Q C6=lQ?@7@==@HQ D92A6lQC64EQm9EEADi^^HHH]=:?<65:?]4@>^4@>A2?J^E96\C@D6?\=2H\7:C>k^2m[ @? %H:EE6Ci k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauEH:EE6C]4@>TauC@D6?07:C>U2>Aj6D966Eldc'ed_eaU2>Aj?6HD:E6>:5la_ac'a'_bdefa'U2>Aj=2?l6?\&$U2>Aj2?49@Cl9EEADTbpTauTauEH:EE6C]4@>TauC@D6?07:C>U2>Aj:?56IldU2>Aj>5dlbcb6ac5gbhfc63b7'6b47egdc32eaec3Q C6=lQ?@7@==@HQ D92A6lQC64EQm9EEADi^^EH:EE6C]4@>^C@D6?07:C>k^2m @C @? u2463@@<i k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]72463@@<]4@>TauC@D6?=2H7:C>TauU2>Aj6D966Eldc'ed_eaU2>Aj?6HD:E6>:5la_ac'a'_bdefa'U2>Aj=2?l6?\&$U2>Aj2?49@Cl9EEADTbpTauTauHHH]72463@@<]4@>TauC@D6?=2H7:C>TauU2>Aj:?56IleU2>Aj>5dl5ba33a6h6ddfh74bg6g'e_35'65_'6'gQ C6=lQ?@7@==@HQ D92A6lQC64EQm9EEADi^^HHH]72463@@<]4@>^C@D6?=2H7:C>^k^2m]k^AmkAmpEE@C?6J p5G6CE:D:?8] !C:@C C6DF=ED 5@ ?@E 8F2C2?E66 2 D:>:=2C @FE4@>6]k^AmkAm':6H D@FC46 G6CD:@? @? k2 9C67lQ9EEAi^^3FD:?6DDH:C6]4@>Qm3FD:?6DDH:C6]4@>k^2mik2 9C67lQ9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'a'_bdefa'^6?^Q C6=lQ?@7@==@HQm9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'a'_bdefa'^6?^k^2mk^AmkAmr~}%pr%i {2FC6?46 #@D6?[ tDB]k^AmkAm!9:==:A z:>[ tDB]k^AmkAm%96 #@D6? {2H u:C>[ !]p]k^Am kAmafd |25:D@? pG6?F6[ c_E9 u=@@Ck^AmkAm}6H *@C<[ }* '__'ek^AmkAm%6=i Wa'aX ege\'_e_k^AmkAm%@== uC66i WgeeX fef\bedbk^AmkAmu2Ii Wa'aX a_a\bgafk^AmkAmk2 9C67lQ>2:=E@i42D6oC@D6?=682=]4@>Qm42D6oC@D6?=682=]4@>k^2mk^AmkAmk2 9C67lQ9EEAi^^HHH]C@D6?=682=]4@>QmHHH]C@D6?=682=]4@>k^2mk^AmkAmzt*(~#si }t( *~#z &}x%ts $%p%t$ }~#%w p|t#xrpk^AmkAmx}s&$%#* zt*(~#si r{p$$ pr%x~} {p($&x% !#~ut$$x~}p{ $t#'xrt$ {tvp{k^AmkAm$~&#rti %96 #@D6? {2H u:C>[ !]p]k^AmkAmr@AJC:89E qFD:?6DD (:C6 a_ac]k^AmkAm!&qi 'a^'_^a_ac _ci'h !|^sx$ri 'a^'_^a_ac _cia_ !|k^AmkAmk2 9C67lQ9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'a'_bdefa'^6?Qm9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'a'_bdefa'^6?k^2mk^Am